Publicaciones en colaboración con investigadores/as de University of Texas Health Science Center at San Antonio (13)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2023

  1. Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation Sparing Approaches: An International Cohort Study

    Journal of Clinical Oncology, Vol. 41, Núm. 10, pp. 1921-1932

2021

  1. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 476-488

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial

    Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197

  2. The urgent need for integrated science to fight COVID-19 pandemic and beyond

    Journal of Translational Medicine, Vol. 18, Núm. 1

2018

  1. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study

    Intensive Care Medicine, Vol. 44, Núm. 9, pp. 1470-1482

  2. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia

    Respiratory Medicine, Vol. 140, pp. 115-121

2016

  1. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer

    New England Journal of Medicine, Vol. 375, Núm. 8, pp. 717-729

2015

  1. Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells

    Stem Cell Reports, Vol. 5, Núm. 6, pp. 1053-1066

2008

  1. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

    Clinical Cancer Research, Vol. 14, Núm. 21, pp. 6895-6906

2005

  1. Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: Do we have enough evidence?

    World Journal of Gastroenterology